Bristol Myers Squibb to Invest up to $850M in Janux Cancer Drug Collaboration
Bristol Myers Squibb has agreed to a collaboration deal with Janux Therapeutics worth up to $850 million to co-develop a novel cancer therapy candidate. The pact includes upfront payments and development milestones, potentially expanding BMY’s oncology pipeline and strengthening its cancer drug portfolio.
1. Strategic AI Partnership with Microsoft Accelerates Oncology Diagnostics
Bristol Myers Squibb has forged a collaboration with Microsoft, leveraging the latter’s imaging technology—currently deployed in 80% of U.S. hospitals—to develop an AI-enabled workflow for earlier lung cancer diagnosis. By combining Microsoft’s advanced image analysis with Bristol Myers Squibb’s oncology and drug‐delivery expertise, the partners aim to reduce time to diagnosis by up to 30% and enhance treatment stratification. Initial pilots are slated to begin in 50 leading cancer centers in the second half of the year, with plans to expand into other tumor types pending proof of concept.
2. Up to $850 Million Janux Collaboration Expands Solid Tumor Portfolio
In a deal valued at up to $850 million, Bristol Myers Squibb has entered into a partnership with Janux Therapeutics to co-develop TRACTr®-based therapies targeting solid tumors. The agreement includes a $100 million upfront payment, development and regulatory milestones of $650 million, and an additional $100 million tied to commercial objectives. Bristol Myers Squibb will lead late-stage clinical development, tapping into Janux’s proprietary T cell receptor activation platform, with the first Phase 1 trial expected to commence in early 2026.
3. Camzyos SCOUT-HCM Data Drive Label Expansion and Double-Digit Revenue Growth
Camzyos (mavacamten) delivered 89% year-over-year revenue growth in the most recent quarter, fueled by strong adoption among hypertrophic cardiomyopathy specialists. Phase 3 SCOUT-HCM topline results demonstrated a statistically significant improvement in exercise capacity, with a 15% mean increase in peak VO2 over placebo. These data support a planned supplemental filing to extend the indication to adolescent obstructive hypertrophic cardiomyopathy patients by mid-2026, potentially expanding the addressable patient population by 40%.
4. Deep Pipeline and Late-Stage Readouts Set Stage for Next Growth Phase
Bristol Myers Squibb’s late‐stage pipeline features four assets with combined peak sales potential exceeding $15 billion. Key readouts include a Phase 3 trial of a next-generation immuno-oncology agent in metastatic melanoma expected in Q3 2026, and a pivotal study of a novel neuroinflammation therapy in multiple sclerosis due in early 2027. Meanwhile, early uptake of Cobenfy for schizophrenia has already surpassed 5,000 patients in its first six months on the market, underscoring the franchise’s diversification beyond oncology.